Related Experiment Video
Updated: May 4, 2026
11:22
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
17.0K
Mesenchymal stem cell therapy in proteoglycan induced arthritis
J F Swart1, S de Roock1, F M Hofhuis2
1Department of Pediatric Immunology and Laboratory of Translational Immunology, Center for Molecular and Cellular Intervention (CMCI), Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Annals of the Rheumatic Diseases
|January 8, 2014
Summary
Mesenchymal stem cell (MSC) injections, administered intraperitoneally or intra-articularly, effectively treat proteoglycan-induced arthritis (PGIA) by modulating immune responses and reducing pathogenic antibodies.
Area of Science:
- Immunology
- Regenerative Medicine
- Rheumatology
Background:
- Proteoglycan-induced arthritis (PGIA) is a non-collagen induced arthritis model.
- Understanding the immunomodulatory effects of mesenchymal stem cells (MSCs) is crucial for developing new arthritis treatments.
Purpose of the Study:
- To investigate the immunosuppressive effects and mechanisms of intraperitoneal (ip) and intra-articular (ia) mesenchymal stem cell (MSC) injections in proteoglycan-induced arthritis (PGIA).
Main Methods:
- MSC were administered ip or ia after arthritis establishment in mice.
- Bioluminescence imaging (BLI) tracked luciferase-transfected MSC.
- Immunomodulatory changes in blood and lymphoid organs were analyzed at various time points.
Main Results:
- Both ip and ia MSC injections showed clinical and histological benefits in established PGIA.
- MSC were retained in the peritoneal cavity or joint for weeks without significant migration.
- MSC treatment decreased pathogenic PG-specific IgG2a antibodies and modulated cytokine profiles (IL-4, IL-10, IFN-γ).
Conclusions:
- MSC treatment, via ip or ia routes, effectively suppresses PGIA.
- MSC induce localized immune deviations and a systemic reduction in pathogenic antibodies.
- These findings highlight the potential of MSC therapy for resistant arthritis.
